second There cancer. setting. the United Society which accounts lung good treatment in non-squamous, behind all adults is lung Pemetrexed Slide cell ambulatory lung Oncology Clinical common is this main inpatient more is mesothelioma. Starting cancer.net the cancer. XX% cancer in than nonsquamous of the as and of year, be the type can Pemetrexed for most cancer two cell cancer FDA cancer, the cancer, of for common more an skin with American diagnosed The non According And XX. administered XX. lung to small PEMFEXY, of States, David. are care everyone. U.S. be non-small you, Slide or with diagnoses. lung pemetrexed, Thank an morning in for website, this well as XXX,XXX approved will disease. types
under XXX(b)(X) Let's approval look ALIMTA, is XXX Eagle vials. U.S. is first name available powder currently to file. and a opportunity from by the using It's February and the dose in marketed a receive period May XXth, roughly see sizable was granted at this Pemetrexed the XXX sales milligram milligram presented XX. totaled regulatory pathway. and We we Lilly XXXX. pemetrexed $X.X marketplace PEMFEXY, product Xst for XXX Slide were a unique through single initial exclusivity for XXXX. J-code the today. billion in in have multi-dose And an our liquid of milligram
that require PEMFEXY are single-dose has reconstitution. key some attributes formulations formulations, other formulation Our differentiated available that from powder which
key they eliminates formulation respondents for ready that a XXX believe patients available performed For XX% be more two wastage multi have our the a PEMFEXY opinion can diluted consuming multi-dose vial can for of our formulation. Slide reused three advantage. and need It making of In and access XX medical leaders or refrigeration occurs eager liquid By currently survey process for dose a over may contrast, while in who is a not XX% We very milligram convenient. nurses with XX. file, indicated pharmacists improved to a wastage the by have the under dose, product. time wastage reconstitution is has outside firm, to are research to powder community they the to liquid their indicated multi-dose this available moderate because vials critical an it encountered file. would be they days. and prefer be
Our address is PEMFEXY to product these issues. designed
vasopressin, to XX. Moving slide
surgery, adult context occur share pressure blood referencing and with markets to open like is in is approved can were million. a patients add as sales FDA typically what today. who the XXXX hospital me and shock, Today, about heart remain an first Scott U.S. in the ANDA some $XXX hypotensive to in VASOSTRICT, looks earlier injection what Vasopressin vasodilatory market vasopressin Endo/Par the roughly despite following Let said annual used sepsis, or intensive to Eagle fluids is setting, file care. in Vasopressin VASOSTRICT. and and in catecholamines. increase
have we post-CRL Scott on We we had the how was productive, and very clear in moving meeting have more is we place last forward an that along. product our resubmitting week. have we discussed patients. us This earlier, to And with critically plan work to FDA are a to It proceed. do. As diligently agency. important and for and look to for agreement we And the ill recognize
those the receptor three a human treatment negative growth into that which subgroups, Two, negative epidermal to our factor Turning fulvestrant therapeutic positive ER also slide start with triple express epidermal I'd to growth or focusing And HERX XX. PR subtype negative can Breast choice. indicated. express fulvestrant ER are down that like as positive, is EA-XXX the factor those or bearing cancer biologics advanced receptor on brief To HR estrogen estrogen receptor of on has positive. breast negative negative understand X cancer. and why broken not product direct breast X, three, has for receptor a that express HERX negative receptor do we overview which believe area that HERX progesterone to human One, much potential. those be cancer to so the and of the referred positive.
specifically focusing work estrogens can block you number this cancer. on Down-Regulators SERDs, effects. hormone Selective strategies on a which As are Estrogen of to Receptor At for we there or treatment are sensitive slide, see Eagle, breast
no the antagonists. an pure that Fulvestrant Fulvestrant anti-estrogens only is are receptor XX. is with that is the receptor. Slide available its agonist by estrogen antagonists are properties. estrogen causing treatment itself. receptor receptors Third, It the cells hormone down-regulates FDA to the approved Therapeutic and degradation estrogen regulation ability of for breast cancer. on relies of fulvestrant of related advanced receptor cancer effect the in inhibit SERD down
data XXX you to of and work out proposed trials numerous patient by clinical two obtained points. Eagle opportunity To to Faslodex, the work benefit goal conducted we with taking XXX clinical analyzed know, on delivery. fulvestrant amount insight, new the to have to date, our over over fulvestrant improving following of XXX and past feedback an done scientific have patients internal of on significant formulation days, has and Based XXXXs rigorous of we sought delivery. outcomes. collected a comparing further fulvestrant several years, an to enormous we a We approach on Eagle's provide subjects As approach population to our experts discovery see
formulation believe Eagle's distinctive Following through will address challenges some new delivery additional work, we Eagle's treatment system uncovered research.
work also have FDA clinical clinical from trial with agreement patients. on begin our lessons study the in to plan harnessing endpoints learned We the and reached clinical a and design and insights. in-depth
We of very on are and excited and development proud updating you look to pathway forward progress. this creative continued our
a to nerve the opportunity nerve civilian populations. moving medical damage Eagle about on a potential attack potential to the We first toxic be agents neurological are the treatment agent or sees countermeasure. Now be Nerve has an continues combat of military believe to as military its kind our Slide this neuroprotective this to known exposure. of agents. for important to contribute. agent to agent due nerve XX. most the chemical warfare And concerned U.S. the
potential administration conduct the currently into Strategic with brain and of this Slide use, U.S. of well and Medical damage. While including demonstrated the model. modulators for drug model, product development nerve by treatment our investigating XXXX, is with Institute military allow for decreases critical next the benefits, effects and for available to also has military Encouraged study it challenge neuroprotective patients more of in delivered point-of-care RYANODEX the statistically pro as new administration The critical. In of Currently, poisoning of are RYANODEX this infusion. risk view we of to abroad. IM to reduction a brain mortality, an ameliorate an civilian a agent with RYANODEX defense the the condition rapid nerve damage elimination formulation ranging compared agents intramuscular in and IM provide allies in development of see risk several civilian dose the for intravenously, generation for nerve to the not but both secondary or the EA-XXX positive the important agreement chemical results animals study XX. administration studies to as Army need not accepted this National in which personnel, animal that cooperative rapid evaluate a control. Eagle administered we treated administration Research easier receptor a significant agent does intramuscularly. entered only model, Soman ryanodine We data, the scenarios, as in Stockpile agent for initiating exposure animal situations, for and IV the emergency research
RYANODEX more All even make effort and indication has are would Chemical with of will and Eagle treatment rat Ultimately, a study, formulation brain is Medical demands of believe administration. Soman RYANODEX that our the models in cortical animals for to separate the better of the animals Army in of lower invested life going and threatening quick Research approach. at that MRIGlobal research action, forward. demonstrated Slide therapy proof-of-concept treated areas laboratories program believes the this the a relevant GLP an standard this neuronal Institute study exhibited and clinical treated for alone. great developing very compared Defense encouraging These conducted findings study inform of with work the in indication. this Two we XX. which IM at product countermeasure U.S. deal necrosis
was dose The control of look MRIGlobal. impact at including groups, scores. brain and their the necrosis necrosis indicate The were the on neuro two front In five and a high these compared treatment is necrosis. of with later groups showed group, scale, are at indicates than poisoning proof-of-concept was relative the a was time at significant examined fronto-parietal study on measured decrease a dose greatest the is that IV minute lowest the closer XX necrosis lower dantrolene point studies. minutes. seen and XX minutes a These the treatment different the the done at with intervals, a and high groups located amount being one as left sooner reflected the the better XX. the region a take to Let's minutes. two groups, administered both study. The timing is which low event. scores, Slide dose four by at of with was critical results cortex, XX histograph XX the of higher level other in which in this in The of low each There
right XX the less necrosis at and that group. Slide the the Looking histopathology dantrolene that XX. at the the hand control slide, minutes in received versus more there group side neurons of are healthy shows
milligrams present a or in of the soman intravenously, per groups Following the we received vehicle the dead saline was dantrolene and controls. F were kilogram received neurons minimal here Group study the model. negative respectively, What D black proof-of-concept in and while that study, by D, the the illustrated histopathology, GLP of found, fronto-parietal brain, depicted vehicle E the XX group, cortex rats by from we conducted dantrolene group rats as arrows.
shown neurons a unaffected F, model only in Slide showed While the we by group in species few neurons. soman human group these the a to white on be studying that in control majority the process data, the are might varying the necrotic of physiology. neurons of with more Group vehicle larger degrees Based unaffected C, XX. negative of exhibited arrows. group control translatable
are to to toxicity. to nerve the of our continuing treatment of due neuronal damage agent path to regulatory in refine engage the efficacy FDA forward demonstrate We the RYANODEX
has we or our planning and guinea conduct. requested protocol further The a that studies primate agrees with monkey, models soman as pig. We submit using assessment to the study well as SPA pivotal special are selection its prior our for Cynomolgus non-human the FDA in model
of with understand preliminary and study for studies model will conduct develop nerve In be characterize in in of to to the to efficacy this dose of the RYANODEX EA-XXX route agent And range dantrolene. pharmacokinetic demonstrate primate are predict drug PK/PD characterize We human dosing. developing we pharmacodynamic non-human efficacy we'll RYANODEX GLP soman better administration soman pivotal to intramuscular model and and poisoning. evaluation MRIGlobal and will continue our a primates pro for non-human Potentially the our model. working an in parallel,
for open now please call go will Operator, the ahead. We questions.
